Clinical anticoagulation therapy effect and safety analysis of atrial fibrillation
心房颤动临床抗凝治疗效果及安全性分析

摘要

目的 研究分析抗凝治疗的实施对于心房颤动的治疗效果、应用价值、治疗安全性。方法 2025年1月-2025年12月就诊心房颤动患者70例，以随机数字表方式分组，对照组（n=35）用药华法林；观察组（n=35）则应用利伐沙班治疗；分析疗效。结果 凝血指标、心功能指标对比，观察组用药治疗后指标改善优于对照组，有显著差异性（P＜0.05）。血液流变学指标汇总数据组别间比较，观察组用药治疗后指标优于对照组（P＜0.05）。统计两组用药不良反应发生率，观察组发生率2.86%（1/35）低于对照组不良反应发生率17.14%（6/35）（P＜0.05）。结论 为心房颤动患者实施抗凝治疗，利伐沙班具有良好药用效果，用药后在对心房颤动做到有效治疗的同时，能够切实保障患者用药安全性。

Abstract

Objective To investigate the therapeutic efficacy, clinical value, and safety profile of anticoagulant therapy in the management of atrial fibrillation (AF).
Methods From January 2025 to December 2025,70 patients with atrial fibrillation were enrolled and randomly assigned using a random number table. The control group (n=35) received warfarin therapy, while the observation group (n=35) was treated with rivaroxaban. Therapeutic efficacy was analyzed.
Results Comparisons of coagulation parameters and cardiac function indices revealed significant improvement in the observation group compared to the control group (P<0.05). Hemorheological parameters showed statistically superior values in the observation group post-treatment (P<0.05). Adverse drug reaction rates were statistically analyzed, with the observation group reporting a lower incidence of 2.86% (1/35) versus the control group’s 17.14% (6/35) (P<0.05).
Conclusion   For patients with atrial fibrillation (AF), rivaroxaban demonstrates favorable pharmacological efficacy in anticoagulation therapy. It not only achieves effective treatment of AF but also ensures robust medication safety for patients.